The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
Open accessAbstract
Colistin and polymyxin B have indistinguishable microbiological activity in vitro, but they differ in the form administered parenterally to patients. Polymyxin B is administered directly as the active antibiotic, whereas colistin is administered as the inactive prodrug, colistin methanesulfonate (CMS). CMS must be converted to colistin in vivo, but this occurs slowly and incompletely. Here we summarize the key differences between parenteral CMS/colistin and polymyxin B, and highlight the clinical implications. We put forth the view that overall polymyxin B has superior clinical pharmacological properties compared with CMS/colistin. We propose that in countries such as the United States where parenteral products of both colistin and polymyxin B are available, prospective studies should be conducted to formally examine their relative efficacy and safety in various types of infections and patients. In the meantime, where clinicians have access to both polymyxins, they should carefully consider the relative merits of each in a given circumstance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Self-citationHancock, R. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)80051-7 · Cited by 1,096
British Journal of Pharmacology
(2010) · British Journal of Pharmacology · doi:10.1111/(issn)1476-5381 · Cited by 920
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Self-citationMoffatt, J. H., Harper, M., Harrison, P., Hale, J. D. F., Vinogradov, E., Seemann, T., Henry, R., Crane, B., St. Michael, F., Cox, A. D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00834-10 · Cited by 812
Self-citationStructure−Activity Relationships of Polymyxin Antibiotics
Velkov, T., Thompson, P. E., Nation, R. L., & Li, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900999h · Cited by 780
Self-citationGaronzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Self-citationLandman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-08 · Cited by 565
Pharmacology of Polymyxins: New Insights into an ‘Old‘ Class of Antibiotics
Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E., & Li, J. (2013) · Future Microbiology · doi:10.2217/fmb.13.39 · Cited by 452
Self-citationNation, R. L., & Li, J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332e672 · Cited by 443
Self-citationSandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit334 · Cited by 430
Self-citationMoskowitz, S. M., Ernst, R. K., & Miller, S. I. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.2.575-579.2004 · Cited by 418
Beceiro, A., Llobet, E., Aranda, J., Bengoechea, J. A., Doumith, M., Hornsey, M., Dhanji, H., Chart, H., Bou, G., Livermore, D. M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00079-11 · Cited by 379
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-06 · Cited by 366
Self-citationGales, A. C., Jones, R. N., & Sader, H. S. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr239 · Cited by 337
Appropriateness and delay to initiate therapy in ventilator-associated pneumonia
Luna, C. M., Aruj, P., Niederman, M. S., Garzón, J., Violi, D., Prignoni, A., Ríos, F., Baquero, S., & Gando, S. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00049105 · Cited by 246
Mohamed, A. F., Karaiskos, I., Plachouras, D., Karvanen, M., Pontikis, K., Jansson, B., Papadomichelakis, E., Antoniadou, A., Giamarellou, H., Armaganidis, A., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06426-11 · Cited by 234
Akajagbor, D. S., Wilson, S. L., Shere-Wolfe, K. D., Dakum, P., Charurat, M. E., & Gilliam, B. L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit453 · Cited by 205
Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
Tam, V. H., Schilling, A. N., Vo, G., Kabbara, S., Kwa, A. L., Wiederhold, N. P., & Lewis, R. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3624-3630.2005 · Cited by 204
In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae
Poudyal, A., Howden, B. P., Bell, J. M., Gao, W., Owen, R. J., Turnidge, J. D., Nation, R. L., & Li, J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn425 · Cited by 185
Self-citationPhe, K., Lee, Y., McDaneld, P. M., Prasad, N., Yin, T., Figueroa, D. A., Musick, W. L., Cottreau, J. M., Hu, M., & Tam, V. H. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02476-13 · Cited by 180
Bergen, P. J., Li, J., Nation, R. L., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm511 · Cited by 140
Self-citationTan, C.-H., Li, J., & Nation, R. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01571-06 · Cited by 138
Self-citationSODIUM SULPHOMETHYL DERIVATIVES OF POLYMYXINS
Barnett, M., Bushby, S. R. M., & Wilkinson, S. (1964) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1964.tb01610.x · Cited by 134
Colistin pharmacokinetics: the fog is lifting
Couet, W. R., Grégoire, N., Marchand, S., & Mimoz, O. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03667.x · Cited by 111
Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity
de Oliveira, M. S., do Prado, G. V. B., Costa, S. F., Grinbaum, R. S., & Levin, A. S. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.07.018 · Cited by 99
Pharmacokinetics and Renal Disposition of Polymyxin B in an Animal Model
Abdelraouf, K., He, J., Ledesma, K. R., Hu, M., & Tam, V. H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01333-12 · Cited by 82
Pharmacokinetics of four different brands of colistimethate and formed colistin in rats
He, H., Li, J.-C., Nation, R. L., Jacob, J., Chen, G., LEE, H. J., Tsuji, B. T., Thompson, P. E., Roberts, K., Velkov, T., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt207 · Cited by 81
Self-citation
Cited by
Poirel, L., Jayol, A., & Nordmann, P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-16 · Cited by 1,447
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Self-citationPolymyxin: Alternative Mechanisms of Action and Resistance
Trimble, M. J., Mlynárčik, P., Kolář, M., & Hancock, R. E. W. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025288 · Cited by 454
Metadata
- Authors
- Nation, R. L., Velkov, T., & Li, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-03
- Volume
- 59
- Issue
- 1
- Pages
- 88-94
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2123135656
- Cited by
- 310
- References
- 29
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.